Plasma fibrinogen, CRP, and hs-CRP levels in patients with benign and borderline ovarian tumours

Objective: Ovarian tumours can be classified as benign, borderline or malignant lesions. The purpose of this study was to assess, inter alia, fibrinogen concentration, and the (C-reactive proteins) and high-sensitivity CRPs (hs-CRPs) levels in the blood serum of patients with ovarian lesions. Study Design: The study involved patients treated laparoscopically and laparotomy in the Gynaecology and Obstetrics Clinical Hospital of the Poznan due to adnexal changes in the form of endometrial cysts and mature teratomas, mucinous cysts, borderline tumors of the ovary, simplex (serosa) cysts or haemorrhagic cysts. Results: The groups differed considerably in fibrinogen (p = 0.022) and d-dimer levels (p = 0.002). Conclusion: Statistically significant differences were found in the fibrinogen and d-dimer profiles among patients with benign and borderline ovarian tumours. However, this requires further investigations in larger patient groups.

Fibrinogen; CRP; hs-CRP; Ovarian tumours

[1] Agic A., Xu H., Finas D., Banz C., Diedrich K., Hornung D.: “Is endometriosis associated with systemic subclinical inflammation?“ Gynecol. Obstet. Invest., 2006, 62, 139.

[2] Wilbur M.A., Shih I.M., Segars J.H., Fader A.N.: “Cancer Implications for Patients with Endometriosis“. Semin. Reprod. Med., 2017, 35, 110.

[3] Crosignani P., Olive D., Bergqvist A., Luciano A. “Advances in the management of endometriosis: an update for clinicians“. Hum. Reprod., 2006,12,179-189.

[4] Yamaguchi K., Mandai M., Toyokuni S., Hamanishi J., Higuchi T., Takakura K., Fujii S.: “Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcino- genesis in the cysts through the iron-induced persistent oxidative stress“. Clin. Cancer. Res., 2008, 14, 32.

[5] Bal J., Gabryś M.S., Jałocha I.: “The role of selected molecular pathways in the pathogenesis of ovarian teratomas”. Postepy. Hig. Med. Dosw., 2009, 63, 242.

[6] Dębski R.: “Nowotwory jajnika czynne hormonalnie”. Borgis - Postępy Nauk Medycznych., 2008, 4, 223.

[7] Sikora-Szczęśniak D., Sikora W.: “Fertility sparing surgical treatment of malignant ovarian tumors in the reproductive age group of women“. Ginekol. Pol., 2012, 83, 27.

[8] Nowak-Markwitz E., Spaczyński M. “Ovarian cancer – modern approach to its origin and histogenesis”. Ginekol. Pol., 2012, 83, 454.

[9] Hefler-Frischmuth K., Lafleur J., Hefler L., Polterauer S., Seebacher V., Reinthaller A., Grimm C.: “Plasma fibrinogen levels in patients with benign and malignant ovarian tumors“. Gynecol. Oncol., 2015, 136, 567.

[10] Polterauer S., Grimm C., Seebacher V., Concin N., Marth C., Tomovski C., et.al.: “Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study”. Oncologist, 2009, 14, 979.

[11] Grabowski J., Markowska J., Tomaszewska K., Fischer N., Nalewaj J.: “Analysis of blood coagulation factors in patients undergoing surgery due to endometrial cysts”. Ginekol. Pol., 2007, 78, 601.

[12] Bromboszcz A., Blacharski J., Lisiewicz J., Liber Z.: “Incidence of hemorrhagic complications and the system of hemostasis in endometriosis“. Ginekol. Pol.,1981, 52, 819.

[13] Chmaj-Wierzchowska K., Kampioni M., Wilczak M., Opala T. “Do inflammatory factors play a significant role in etiopathogenesis of endometrial cysts? Part 1”. Ann. Agric. Environ. Med., 2013, 20, 854.

[14] Hefler L., Concin N., Hofstetter G., Marth C., Mustea A., Sehouli J., et al.: “Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer”. Clin. Cancer. Res., 2008, 14, 710

[15] Ose J., Schock H., Tjønneland A., Hansen L., Overvad K., Dossus L., et al.: “Inflammatory markers and risk of epithelial ovarian cancer by tumor subtypes: The EPIC Cohort”. Cancer. Epidemiol. Biomarkers. Prev., 2015, 24, 951.

[16] Helzlsouer K.J., Erlinger T.P., Platz E.A.: “C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study”. Eur. J. Cancer, 2006, 42, 704.

[17] Hefler-Frischmuth K., Hefler L.A., Heinze G., Paseka V., Grimm C., Tempfer C.B.: “Serum C-reactive protein in the differential diagnosis of ovarian masses“. Eur. J. Obstet. Gynecol. Reprod. Biol., 2009, 147, 65.

[18] Xavier P., Belo L., Beires J., Rebelo I., Martinez-de-Oliveira J., Lunet N., Barros H.: “Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis”. Arch. Gynecol. Obstet., 2006, 273, 227.

[19] Chmaj-Wierzchowska K., Stryjakowska K., Szymanowski K., Opala T.: “The infectious factor of endometrial cysts - a preliminary research”. Pol. Prz. Nauk. Zdr., 2008, 4, 233.

[20] Abdollahi A., Ali-Bakhshi A., Farahani Z. “Concentration study of high sensitive C - reactive protein and some serum trace elements in patients with benign and malignant breast yumor”. Int. J. Hematol. Oncol. Stem. Cell. Res., 2015, 9, 180.

[21] Bakacak M., Köstü B., Ercan Ö., Bostancı M.S., Kıran G., Aral M., Çıralık H., Serin S.: “High-sensitivity C-reactive protein as a novel marker in early diagnosis of ovarian torsion: an experimental study“. Arch. Gynecol. Obstet., 2015, 291, 99.